-
A global leader in providing trusted information and insights to accelerate the pace of innovation.This report identifies seven emerging medical science innovators seeking solutions to targets of untreatable diseases. This report utilizes data and analysis from BioWorld.
BioWorld is a suite of award-winning news services that provide actionable information on the most innovative therapeutics and medical technologies developed and published by Clarivate. This report uses data and insights from Clarivate and BioWorld, combined with analysis of drug benefits, funding, R&D activities, and more to find out what makes these companies stand out and which companies to watch. We are looking into why.
Therapies that target or contain RNA to combat disease have gained prominence over the past decade, with further prominence during the global COVID-19 pandemic, with the regulatory approval of mRNA vaccines. bathed in Success in rare diseases that typically do not respond well to traditional approaches highlights RNA therapy. This new treatment has shown benefits such as fewer side effects, lower costs, and improved efficacy and accessibility, giving hope to patients and physicians.
However, RNA technology presents challenges such as instability, high innate immunogenicity, and inherent limitations such as targeting challenges. Despite these challenges, the space remains promising. In this report, Clarivate has identified seven innovative, recently founded RNA technology companies that are developing solutions to combat currently untreatable targets in space.